Eli Lilly and Co (BSP:LILY34)
R$ 130.52 -2.2 (-1.66%) Market Cap: 3.72 Til Enterprise Value: 3.84 Til PE Ratio: 113.84 PB Ratio: 56.38 GF Score: 73/100

Eli Lilly and Co at Cowen Health Care Conference Transcript

Mar 11, 2019 / 04:00PM GMT
Release Date Price: R$16.19
Stephen Michael Scala;Joshua L. Smiley
Cowen and Company, LLC, Research Division - MD and Senior Research Analyst;Eli Lilly and Company - Senior VP & CFO<

Good afternoon. We're very, very happy to have Eli Lilly back at the Cowen Conference. Joining us for this conference is Josh Smiley, who is Executive Vice President and Chief Financial Officer.

Before we start the Q&A and please chime in with questions anywhere along the line. I'd just like to note that Lilly has been one of Cowen's longest-standing recommended stocks. We upgraded this stock in April of 2014, so nearly 5 years, and we believe it's as compelling now as any time in that 5-year period because we like the new product story, we like the financial outlook, we like the fact that management consistently delivers. And we like the fact that over decades, Lilly has that creative spark that we can look forward to it bringing an innovative pipeline into the future. We don't think many companies have that, Lilly does, and that we find very appealing.

So with that, Josh, thanks for coming.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot